CD274 and non-small cell lung carcinoma: Investigation is now undergoing to define the value of plasma PD-L1 protein levels as a predictive biomarker of prognosis in NSCLC and also as a reliable companion diagnostics for individualized treatment with ICBT (Zhu and Lang, 2017).